2,4,5-Trifluorobenzyl bromide is an important intermediate in the synthesis of sitagliptin. Sitagliptin is the first dipeptidyl peptidase-IV (DPP-IV) inhibitor developed by Merck and approved by the US FDA in October 2006 for the treatment of non-insulin-dependent (type II) diabetes. 2,4,5-trifluorobenzyl bromide is prepared by bromomethylation of 1,2,4-trifluorobenzene as raw material, which has more waste and needs to use highly toxic cyanide, and the process has certain safety risks.